Bristol-Myers Squibb (BMY) Immuno-Oncology 'Paradigm Changing' - Goldman
Tweet Send to a Friend
Goldman Sachs today maintained a Conviction Buy on Bristol-Myers Squibb Co. (NYSE: BMY) and raised its price target to $55.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
